Literature DB >> 20372039

Nationwide surveillance study of vancomycin intermediate Staphylococcus aureus strains in Korean hospitals from 2001 to 2006.

Gyungtae Chung1, Jeongok Cha, Sunyoung Han, Heesun Jang, Kyeongmin Lee, Jaeil Yoo, Jeongsik Yoo, Hongbin Kim, Soohoon Eun, Bongsu Kim, Ok Park, Yeong seon Lee.   

Abstract

We investigated the prevalence and the molecular characteristics of vancomycin-intermediate Staphylococcus aureus (VISA) among methicillin-resistant Staphylococcus aureus (MRSA) strains isolated from clinical samples at tertiary or general hospitals participating in a nationwide surveillance program for VISA and vancomycin-resistant Staphylococcus aureus (VRSA) in Korea during an 8-week period in each year from 2001 to 2006. Of 41,639 MRSAs isolated, 37,856 were screened and 169 grew on brain heart infusion agar supplemented with 4 microg/ml vancomycin. A vancomycin MIC of 4 microg/ml was confirmed for 33 VISA isolates of the 169 isolates. Eighteen of the 33 isolates were classified as hetero-VISA (hVISA) by the population analysis profile (PAP) method. All VISA isolates were susceptible to linezolid, tigecycline, and quinupristin-dalfopristin. Most VISA isolates (MIC 4 microg/ml) showed a PFGE C pattern with sec, seg, and sei enterotoxin genes, including ST5-SCCmec type II, or a PFGE A pattern with sea, including ST239-SCCmec type III.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20372039

Source DB:  PubMed          Journal:  J Microbiol Biotechnol        ISSN: 1017-7825            Impact factor:   2.351


  12 in total

Review 1.  Systematic review and meta-analysis of the significance of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates.

Authors:  Sebastiaan J van Hal; David L Paterson
Journal:  Antimicrob Agents Chemother       Date:  2010-11-15       Impact factor: 5.191

2.  Characterization of methicillin-resistant Staphylococcus aureus strains recovered from a phase IV clinical trial for linezolid versus vancomycin for treatment of nosocomial pneumonia.

Authors:  Rodrigo E Mendes; Lalitagauri M Deshpande; Davida S Smyth; Bo Shopsin; David J Farrell; Ronald N Jones
Journal:  J Clin Microbiol       Date:  2012-09-12       Impact factor: 5.948

3.  Prevalence of amino acid changes in the yvqF, vraSR, graSR, and tcaRAB genes from vancomycin intermediate resistant Staphylococcus aureus.

Authors:  Jae Il Yoo; Jung Wook Kim; Gi Su Kang; Hwa Su Kim; Jung Sik Yoo; Yeong Seon Lee
Journal:  J Microbiol       Date:  2013-04-27       Impact factor: 3.422

4.  First report of vancomycin-intermediate resistance in sequence type 72 community genotype methicillin-resistant Staphylococcus aureus.

Authors:  Doo Ryeon Chung; Jin Yang Baek; Hyun Ah Kim; Min Hee Lim; So Hyun Kim; Kwan Soo Ko; Cheol-In Kang; Kyong Ran Peck; Nam Yong Lee; Jae-Hoon Song
Journal:  J Clin Microbiol       Date:  2012-05-02       Impact factor: 5.948

5.  The efficacy and safety of arbekacin and vancomycin for the treatment in skin and soft tissue MRSA infection: preliminary study.

Authors:  Ji-Hee Hwang; Ju-Hyung Lee; Mi-Kyoung Moon; Ju-Sin Kim; Kyoung-Suk Won; Chang-Seop Lee
Journal:  Infect Chemother       Date:  2013-03-29

6.  Clinical and Molecular Characterization of Invasive Heteroresistant Vancomycin-Intermediate Staphylococcus aureus Infections in Korean Hospitals.

Authors:  Eu Suk Kim; In-Gyu Bae; Jeong Eun Cho; Yun Jung Choi; Il-Hwan Kim; Gi-Su Kang; Hye-yun Sin; Kyoung-Ho Song; Chulmin Park; Dong-Gun Lee; Moonsuk Kim; Kyoung Un Park; Hong Bin Kim
Journal:  J Clin Microbiol       Date:  2015-12-16       Impact factor: 5.948

7.  The usefulness of arbekacin compared to vancomycin.

Authors:  J-H Hwang; J-H Lee; M-K Moon; J-S Kim; K-S Won; C-S Lee
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-11-29       Impact factor: 3.267

8.  Detection of Staphylococcus aureus with an intermediate profile to vancomycin (VISA) isolate from Santa Maria, RS.

Authors:  Jaciane Baggiotto Marques; Tanise Vendruscolo Dalmolin; Pauline Cordenonsi Bonez; Vanessa Albertina Agertt; Marli Matiko Anraku de Campos; Roberto Christ Vianna Santos
Journal:  Braz J Microbiol       Date:  2013-05-31       Impact factor: 2.476

9.  Global prevalence and distribution of vancomycin resistant, vancomycin intermediate and heterogeneously vancomycin intermediate Staphylococcus aureus clinical isolates: a systematic review and meta-analysis.

Authors:  Aref Shariati; Masoud Dadashi; Majid Taati Moghadam; Alex van Belkum; Somayeh Yaslianifard; Davood Darban-Sarokhalil
Journal:  Sci Rep       Date:  2020-07-29       Impact factor: 4.379

Review 10.  Systematic Review and Meta-Analysis of the Epidemiology of Vancomycin-Intermediate and Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Isolates.

Authors:  Shanshan Zhang; Xiaoxi Sun; Wenjiao Chang; Yuanyuan Dai; Xiaoling Ma
Journal:  PLoS One       Date:  2015-08-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.